Effect of intralesional alpha 2-interferon on actinic keratoses

Biologics in Dermatologic Therapy - An Update

“…Thus IFNα also exhibits antiproliferative and immunomodulatory functions. [12] Recombinant IFNα is given as a subcutaneous or intramuscular injection to treat verruca vulgaris,[13] condyloma acuminatum,[14] cutaneous T cell lymphoma,[15] Kaposi's sarcoma (AIDS related),[16] melanoma,[17] basal cell carcinoma,[18] squamous cell carcinoma,[19] actinic keratosis,[20] Behçet's disease,[21] hemangiomas[22] and keloids. [23] The injections are usually given thrice weekly and the dose (depending on the condition being treated) varies from low-dose therapy for condyloma acuminatum[24] to high-dose therapy for melanoma.…”

Topical diclofenac in the treatment of actinic keratoses

“…IFN consists of types α and β, which are immune mediators whose normal function is to defend the cell from viral infection. The therapeutic benefit of intralesional injections of IFN in patients with AK is well established 10 . The mechanism by which the suppression of IFN occurs in AK lesions, however, has only recently been shown to include the down‐regulation of IFN‐stimulated signal molecules and a subsequent decreased response to endogenous IFN 11…”

Interferon-induced sarcoidosis

“…These modified IFNs are expected to have more favourable therapeutic outcomes during treatment of certain conditions such as chronic hepatitis C (CHC) virus infection (5). Recently, IFNs has been also evaluated as a novel therapeutic modalities for other conditions such as systemic sclerosis (6), small cell lung carcinoma (7), malignant mesothelioma (8), malignant pleural effusions (9), pulmonary fibrosis (10,11), multidrug‐resistant tuberculosis (12,13), actinic keratoses (14, 15), atopic dermatitis (16), basal cell carcinomas (17), Behcet's disease (18), mycosis fungoides (19), discoid lupus erythematosus (20), haemangiomas (21) and psoriasis (22).…”